Kiromic Biopharma Inc (KRBP)

NASDAQ
3.490
-0.140(-3.86%)
  • Volume:
    50,088
  • Bid/Ask:
    3.460/3.500
  • Day's Range:
    3.470 - 3.545

KRBP Overview

Prev. Close
3.63
Day's Range
3.47-3.545
Revenue
-
Open
3.64
52 wk Range
2.64-18.26
EPS
-
Volume
50,088
Market Cap
56.04M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
334,450
P/E Ratio
-
Beta
-
1-Year Change
-
Shares Outstanding
15,437,689
Next Earnings Date
-
What is your sentiment on Kiromic Biopharma Inc?
or
Vote to see community's results!

Kiromic Biopharma Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellStrong SellSellSellSell
Technical IndicatorsStrong SellStrong SellSellSellSell
SummaryStrong SellStrong SellSellSellSell

Kiromic Biopharma Inc Company Profile

Kiromic Biopharma Inc Company Profile

Employees
11

Kiromic BioPharma, Inc., a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1; and chimeric gamma delta PD1 T cell switch receptor therapy. It has license agreements with Mercer University; CGA 369 Intellectual Holdings, Inc.; and Longwood University, as well as research and development collaboration agreements with Molipharma, S.R.L. and Leon Office (H.K.). The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

Read More
  • Can anyone tell me if the YATSEN Ticket ysg is a good bet. It entered the IPO Thursday and is $ 17 now.
    0
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.